Cambridge’s Camp4 Therapeutics Inc. and Waltham’s Upstream Bio Inc. will both make their debuts on the public markets Friday.

AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion.

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

High DAR Dual-Payload ADC Sutro unveils unique cell-free capabilities Proprietary cell-free platform enables the design of ...

The offering will fund testing of a potential rival to Amgen’s Tezpire and is already the sixth for an immune drug developer ...

The treatment of metabolic dysfunction-associated steatohepatitis (MASH) has proven challenging, with many compounds failing during development for various reasons. However, with the recent ...

Upstream asserts that verekitug could offer advantages over Tezpire, including potentially greater potency and longer dosing intervals. The company is testing intervals of 12 and 24 weeks in its ...

Iota Biosciences, a subsidiary of Astellas Pharma, announced that it received FDA investigational device exemption (IDE) for ...

Japanese nationals have become increasingly jittery over traveling to China after several Japanese were targeted in violent attacks.Some of the products that Ken Kato sells though his funerary ...

In August, an executive at Japanese drug maker Astellas Pharma was indicted for espionage. Earlier in 2023, Beijing fined ...

Dublin organisations were among the big winners at the second Menopause Workplace Excellence Awards, staged in the capital ...